CDXS (Codexis Bio) Return on Gross Profit

CDXS (Codexis, Inc.) - company brandmark

Codexis, Inc. (CDXS) is a recognized expert in developing protein catalysts for top pharma behemoths amid growing demand for biosynthesis. This GURU.Markets gross margin chart demonstrates cost efficiency, where 81.30 characterizes this valuation parameter. The company achieves cost optimization by utilizing certified contractors to scale enzyme production from its California complex.

CDXS - Codexis, Inc. Return on Gross Profit over the range 07/04/2022 - 11/19/2026

Financial and market metric breakdowns for Codexis, Inc. (CDXS)

- current quotes and average value forecast:
- business market valuation indicators:
Basic company analysis:Codexis, Inc.
Mass-produced product of Codexis Bio

Gross margin measures the portion of revenue remaining after covering direct production costs, reflecting the efficiency of cost management and the business's pricing power. For Codexis, Inc. (CDXS), which partners with pharmaceutical behemoths in the biocatalysts segment, the gross profit margin trend confirms the company's ability to monetize its technological superiority in drug synthesis, serving as a key indicator of the model's fundamental stability.

Direct competitors

Return on Gross Profit Tempus AI Inc|QGEN (Qiagen NV) - Gross Margin|Return on Gross Profit Ionis Pharma (IONS)|Gross Profitability Repligen Corp (RGEN)|RNA - Gross Profit Margin|crisprtx.com - Return on Gross Profit|Gross Profit Rate WGS|RARE - Gross Profitability|Beam Tx (BEAM) - Return on Gross Profit|SRPT (Sarepta Therapeutics Inc) - Return on Gross Profit|TWST: Gross Profit Ratio|TXG (10xgenomics.com) - Gross Margin|NTLA (Intellia Therapeutics, Inc.) - Gross Profit Ratio|Gross Profitability Stoke Corp (STOK)|Return on Sales by Gross Profit BioLife|Gross Margin WVE (Wave Life Sciences Ltd)|MAZE: Gross Return on Sales|Sionna Therapeutics, Inc. - Gross Margin|Gross Profit Rate PRME (Prime Medicine Inc)|TSHA (Taysha Gene Therapies, Inc.) - Return on Gross Profit|QURE - Return on Sales by Gross Profit|MGTX (MeiraGTx Corp) - Gross Margin|Gross Profit Margin REGENXBIO Inc. RGNX|Gross Profitability Solid Biosciences (SLDB)|Ocugen Corp - Gross Return on Sales|Gross Profitability Pacific Biosciences PACB|Gross Profit Ratio BNTC (Benitec)|Design Corp - Gross Margin|Rocket Pharmaceuticals - Gross Profit Ratio|Gross Return on Sales 4D Molecular Therapeutics, Inc.|Gross Profit Margin Lexeo Therapeutics (LXEO)|KRRO (Korro Bio, Inc.) - Gross Margin|Gross Profit Margin Editas EDIT|Gross Margin SLN|ProQR Therapeutics - Gross Return on Sales|Gross Profitability Sangamo SGMO|NAUT: Gross Return on Sales|MGX: Return on Gross Profit|Gross Profit Margin Precision BioSciences|GBIO (generationbio.com) - Return on Gross Profit|Gross Profit Margin boundlessbio.com (BOLD)|XCUR (exicuretx.com) - Gross Margin|Gross Return on Sales IMNN (Imunon, Inc.)|Gross Margin PHIO|MBIO - Gross Profit Margin|Gross Margin RNAZ (TransCode Therapeutics)|bionanogenomics.com (BNGO) - Gross Profit Margin|Applied DNA - Gross Margin|Gross Profit Margin Bluebird Bio|ImmunoPrecise (IPA) - Gross Profitability|Gross Profitability Margin OMGA (Omega)|Gross Profitability Singular Genomics Systems|Gross Profit Margin regulusrx.com RGLS|Gross Profitability Syros Pharmaceuticals Inc. (SYRS)|Return on Sales by Gross Profit Codex DNA|Gross Profitability TRACON TCON|Unity Biotechnology, Inc - Gross Profitability